Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties
Paweł Zajdel, Krzysztof Marciniec, Grzegorz Satała, et al.
ACS Medicinal Chemistry Letters (2016) Vol. 7, Iss. 6, pp. 618-622
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Serotonin receptors in depression and anxiety: Insights from animal studies
Elżbieta Żmudzka, Kinga Sałaciak, Jacek Sapa, et al.
Life Sciences (2018) Vol. 210, pp. 106-124
Closed Access | Times Cited: 153
Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status
Hilda Ferrero, Maite Solas, Paul T. Francis, et al.
CNS Drugs (2016) Vol. 31, Iss. 1, pp. 19-32
Closed Access | Times Cited: 92
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review
Zixin Ye, Chen Lulu, Xiangchang Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 47
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases
David Vanda, Paweł Zajdel, Miroslav Soural
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111569-111569
Closed Access | Times Cited: 75
Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 8, pp. 823-842
Closed Access | Times Cited: 47
Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer’s disease
Katarzyna Kucwaj‐Brysz, Hanna Baltrukevich, Kinga Czarnota, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 49, pp. 128275-128275
Open Access | Times Cited: 35
Novel non-sulfonamide 5-HT 6 receptor partial inverse agonist in a group of imidazo[4,5- b ]pyridines with cognition enhancing properties
David Vanda, Miroslav Soural, Vittorio Canale, et al.
European Journal of Medicinal Chemistry (2017) Vol. 144, pp. 716-729
Closed Access | Times Cited: 44
Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects
Paweł Zajdel, Tomasz Kos, Krzysztof Marciniec, et al.
European Journal of Medicinal Chemistry (2018) Vol. 145, pp. 790-804
Closed Access | Times Cited: 44
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
Ramakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 1843-1859
Closed Access | Times Cited: 42
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Anna Partyka, Joanna Gołębiowska, Krzysztof Marciniec, et al.
Pharmacological Reports (2025)
Closed Access
Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties
Jakub Staroń, Rafał Kurczab, Dawid Warszycki, et al.
European Journal of Medicinal Chemistry (2019) Vol. 185, pp. 111857-111857
Open Access | Times Cited: 35
Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes
Ian Steinke, Nila Ghanei, Manoj Govindarajulu, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 31
mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment
Pierre-Yves Martin, Stéphane Doly, Al Mahdy Hamieh, et al.
Progress in Neurobiology (2020) Vol. 193, pp. 101846-101846
Open Access | Times Cited: 28
Recent Advances in Biological Active Sulfonamide based Hybrid Compounds Part C: Multicomponent Sulfonamide Hybrids
Reihane Ghomashi, Shakila Ghomashi, Hamidreza Aghaei, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 37, pp. 4181-4255
Closed Access | Times Cited: 17
Dual 5-HT6 and D3 Receptor Antagonists in a Group of 1H-Pyrrolo[3,2-c]quinolines with Neuroprotective and Procognitive Activity
Katarzyna Grychowska, Séverine Chaumont‐Dubel, Rafał Kurczab, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 7, pp. 3183-3196
Open Access | Times Cited: 29
The Constitutive Activity of Spinal 5-HT6 Receptors Contributes to Diabetic Neuropathic Pain in Rats
Nazarine Mokhtar, Marcin Drop, Florian Jacquot, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 364-364
Open Access | Times Cited: 8
The impact of the halogen bonding on D 2 and 5-HT 1A /5-HT 7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties
Anna Partyka, Rafał Kurczab, Vittorio Canale, et al.
Bioorganic & Medicinal Chemistry (2017) Vol. 25, Iss. 14, pp. 3638-3648
Closed Access | Times Cited: 28
Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro
Annamaria Lubelska, Gniewomir Latacz, Magdalena Jastrzębska‐Więsek, et al.
Molecules (2019) Vol. 24, Iss. 24, pp. 4472-4472
Open Access | Times Cited: 23
Sustainable Synthesis of a Potent and Selective 5-HT7 Receptor Antagonist Using a Mechanochemical Approach
Vittorio Canale, Valeria Frisi, Xavier Bantreil, et al.
The Journal of Organic Chemistry (2020) Vol. 85, Iss. 16, pp. 10958-10965
Open Access | Times Cited: 22
Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States
David Vanda, Vittorio Canale, Séverine Chaumont‐Dubel, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 2, pp. 1180-1196
Closed Access | Times Cited: 20
2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design
Adam S. Hogendorf, Agata Hogendorf, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2019) Vol. 179, pp. 1-15
Closed Access | Times Cited: 21
Constitutive Activity of Serotonin Receptor 6 Regulates Human Cerebral Organoids Formation and Depression-like Behaviors
Qinying Wang, Xiaoxu Dong, T. Hu, et al.
Stem Cell Reports (2020) Vol. 16, Iss. 1, pp. 75-88
Open Access | Times Cited: 19
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13279-13298
Open Access | Times Cited: 17
1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R Antagonists: Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity
Vittorio Canale, Wojciech Trybała, Séverine Chaumont‐Dubel, et al.
Biomolecules (2022) Vol. 13, Iss. 1, pp. 12-12
Open Access | Times Cited: 12
2-Phenyl-1H-pyrrole-3-carboxamide as a New Scaffold for Developing 5-HT6 Receptor Inverse Agonists with Cognition-Enhancing Activity
Marcin Drop, Vittorio Canale, Séverine Chaumont‐Dubel, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 7, pp. 1228-1240
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top